---
title: "SPDB Sticks to Its Buy Rating for Akeso, Inc. (9926)"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/305917762.md"
description: "SPDB analyst maintained a Buy rating on Akeso, Inc. yesterday and set a price target of HK$130.00.In addition to SPDB, Akeso, Inc. also received a Buy from CMB International Securities’s Jill Wu in a report issued yesterday. However, on November 2, Bernstein maintained a Hold rating on Akeso, Inc. (HKEX: 9926)."
datetime: "2026-11-18T05:25:19.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/305917762.md)
  - [en](https://longbridge.com/en/news/305917762.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/305917762.md)
generator: "portal-rs"
---

# SPDB Sticks to Its Buy Rating for Akeso, Inc. (9926)

SPDB analyst maintained a Buy rating on Akeso, Inc. yesterday and set a price target of HK$130.00.

In addition to SPDB, Akeso, Inc. also received a Buy from CMB International Securities’s Jill Wu in a report issued yesterday. However, on November 2, Bernstein maintained a Hold rating on Akeso, Inc. (HKEX: 9926).

### Related Stocks

- [09926.HK](https://longbridge.com/en/quote/09926.HK.md)
- [600000.CN](https://longbridge.com/en/quote/600000.CN.md)
- [AB.US](https://longbridge.com/en/quote/AB.US.md)

## Related News & Research

- [Akeso Says FDA Complete Response Letter May Explain Unusual Share Price Moves](https://longbridge.com/en/news/305612661.md)
- [China Accepts Akeso’s Ivonescimab Application for Biliary Tract Cancer](https://longbridge.com/en/news/305757945.md)
- [Nomura Downgrades AKESO  to Neutral, Cuts TP to HKD94](https://longbridge.com/en/news/305613245.md)
- [Akeso's Gumokimab Wins China Approval for Active Ankylosing Spondylitis](https://longbridge.com/en/news/305622467.md)
- [UBS: AKESO  Partner Receives FDA Complete Response Letter for ivonescimab Plus Chemotherapy BLA, Slightly Negative](https://longbridge.com/en/news/305605601.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**